Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Six-week prednisolone for immune checkpoint inhibitor-associated lung disorder
jRCT1041190029Phase 2Recruiting
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prednisolone in Checkpoint inhibitor pneumonitis (CIP) and alveolitis. Primary endpoint: Control rate at 6 weeks after the start of prednisolone treatment. Started May 2019; status: recruiting.
02
Drugs
prednisolone
03
Conditions
Checkpoint inhibitor pneumonitis (CIP)alveolitis
Beyond the preview
Go deeper on jRCT1041190029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041190029.